GlycoMimetics (NASDAQ:GLYC) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 12.5 percent increase over losses of $(0.32) per share from the same period last year.
Century Therapeutics Receives Study May Proceed Notification From FDA For CNTY-101
– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA –
– First cell product candidate engineered with six
